Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics and keeping the price target at $10.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Charles Zhu has given his Buy rating due to a combination of factors including the promising progress of Compass Therapeutics’ COMPANION-002 trial. The trial, which is evaluating tovecimig for second-line biliary tract cancer (BTC) patients, has shown potential clinical benefits with a median follow-up of approximately 19 months. This is significant as it surpasses the overall survival rates observed in similar studies, suggesting a positive outlook for the treatment.
Additionally, Zhu highlights the underappreciated market opportunity for BTC treatments, as current market assessments often overlook the full scope of the disease’s prevalence. With an estimated 23,000 annual US patients, there is a substantial market potential that Compass Therapeutics could tap into. Furthermore, the anticipated pricing strategy for tovecimig could provide financial upside, and ongoing regulatory engagements, both domestically and internationally, are expected to support future growth prospects.